National

Pro Rata

Axios Pro Rata

Clinical research treating mental illness with psychedelics has been happening for decades, but now there's a group of companies exclusively focused on using LSD and other psychedelics to treat mental health disorders.

Axios Re:Cap digs into the argument for legalizing prescription psychedelics, and the treacherous FDA approval path, with MindMed CEO JR Rahn, whose company recently listed on the Nasdaq.

The push to legalize psychedelics for mental health

Several companies are developing psychedelic drugs for mental health treatment, but the path to legalization will be treacherous.

Mental health

Axios Re:Cap

<p>Clinical research treating mental illness with psychedelics has been happening for decades, but now there&#x27;s a group of companies exclusively focused on using LSD and other psychedelics to treat mental health disorders.</p><p><strong>Axios Re:Cap</strong> digs into the argument for legalizing prescription psychedelics, and the treacherous FDA approval path, with MindMed CEO JR Rahn, whose company recently listed on the Nasdaq.</p><div><div><iframe frameborder="no" height="200" scrolling="no" src="https://playlist.megaphone.fm?e=AXIOS6239826535" width="100%"></iframe></div><div style="display:none"></div></div><span data-ad-status="NO_AD_LENGTH" data-ad-type="midStoryAd"></span>

Podcasts

The U.S. faces a range of health care flashpoints — unaffordable drugs, opioids, vaping — as we debate whether to adopt universal care. For now, the Affordable Care Act is the law of the land, but Republicans want to issue it a final death blow.

Health

After a record economic expansion, the coronavirus pandemic sent the U.S. economy into a recession as unemployment soared to staggering heights. The country now faces urgent questions about how much stimulus is needed for reeling consumers and businesses, and what a recovery might look like.

The push to legalize psychedelics for mental health

Go deeper